Update in postmenopausal osteoporosis management


Why we should use tools to evaluate osteoporosis risk? Olivier Bruyère (ULG)

Role of biochemical assessments in the management of osteoporosis. Etienne Cavalier (ULiège) Slides Belgian Menopause society avril 2022

Bisphosphonates vs. denosumab: Advantages and risks. Charlotte Verroken (UGent) Bisphosphonates vs. denosumab

MHT and SERMS for osteoporosis: do they still have a place? Serge Rozenberg (ULB-VUB) BMS osteoporosis 30.4.22 (1)

Satellite symposium UCB Romososumab: Results of trials, positioning and indications Evelien Gielen

No data was found

Latest news

prediction models for primary ovarian insufficiency (POI) in long-term survivors of childhood cancer by Cindy Im et al Lancet Oncol 2023 Nov 13